Role of hypoxia-inducible factors in acute kidney injury

Nephron - Clinical Practice

Volumn 127, Issue 1-4, 2014, Pages 70-74

  Andringa, Kelly K ^a   Agarwal, Anupam ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Hypoxia; Hypoxia inducible factor; von Hippel Lindau proteins

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ERYTHROPOIETIN; GLUCOSE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; ACETAZOLAMIDE; BARBITURIC ACID DERIVATIVE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DAPRODUSTAT; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; GLYCINE; HIF-2 PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; VHL PROTEIN, HUMAN; VHLH PROTEIN, MOUSE;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; CELL HYPOXIA; CONFERENCE PAPER; ENERGY METABOLISM; ERYTHROPOIESIS; HUMAN; HYPOXEMIA; HYPOXIA; MEDIATOR RELEASE; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ADAPTATION; ALTITUDE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; KIDNEY; METABOLISM; MOUSE; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; RAT; REPERFUSION INJURY; VASCULARIZATION;

ACETAZOLAMIDE; ACUTE KIDNEY INJURY; ADAPTATION, PHYSIOLOGICAL; ALTITUDE; ANIMALS; BARBITURATES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CLINICAL TRIALS, PHASE II AS TOPIC; GENE EXPRESSION REGULATION; GLYCINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MICE; RATS; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84927700951     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000363669     Document Type: Conference Paper

References (14)

1. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480.
2. Haase VH: Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 2006; 291:F271-F281.
3. Haase VH: The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des 2009; 15: 3895-3903.
4. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A: Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51: 553-555.
5. Kapitsinou PP, Jaffe J, Michael M, Swan CE, Duffy KJ, Erickson-Miller CL, Haase VH: Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol 2012; 302:F1172-F1179.
6. Schley G, Klanke B, Schodel J, Kroning S, Turkogly G, Beyer A, Hagos Y, Amann K, Burckhardt BC, Burzlaff N, Eckardt KU, Willam C: Selective stabilization of HIF1α in renal tubular cells by 2-oxyglutarate analogues. Am J Pathol 2012; 181: 1595-1606.
7. An Y, Zhang JZ, Han J, Yang HP, Tie L, Yang XY, Xiaokaiti Y, Pan Y, Li XJ: Hypoxia-inducible factor-1α dependent pathways mediate the renoprotective role of acetazolamide against renal ischemia-reperfusion injury. Cell Physiol Biochem 2013; 32: 1151-1166.
8. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A: The story so far: molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 2004; 286:F425-F441.
9. Nangaku M, Rosenberger C, Heyman SN, Eckardt KU: Regulation of hypoxia-inducible factor in kidney disease (review). Clin Exp Pharmacol Physiol 2013; 40: 148-157.
10. Clinical Trials Government website Identifier NCT01920594: Study of GSK1278863 to reduce ischemic events in patients undergoing thoracic aortic aneurysm repair. http://clinicaltrials. gov/ct2/show/NCT01920594?term= NCT01920594&rank=1.
11. Clinical Trials Government website Identifier NCT01406340: Assessment of the pharmacokinetics of GSK1278863 and metabolites in normal subjects and subjects with renal impairment. http://clinicaltrials.gov/ct2/show/ NCT01406340.
12. Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge RL: Genetic evidence for high-altitude adaptation in Tibet. Science 2010; 329: 72-74.
13. Yi X, Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, Xu X, Jiang H, Vinckenbosch N, Korneliussen TS, Zheng H, Liu T, He W, Li K, Luo R, Nie X, Wu H, Zhao M, Cao H, Zou J, Shan Y, Li S, Yang Q, Asan, Ni P, Tian G, Xu J, Liu X, Jiang T, Wu R, Zhou G, Tang M, Qin J, Wang T, Feng S, Li G, Huasang, Luosang J, Wang W, Chen F, Wang Y, Zheng X, Li Z, Bianba Z, Yang G, Wang X, Tang S, Gao G, Chen Y, Luo Z, Gusang L, Cao Z, Zhang Q, Ouyang W, Ren X, Liang H, Zheng H, Huang Y, Li J, Bolund L, Kristiansen K, Li Y, Zhang Y, Zhang X, Li R, Li S, Yang H, Nielsen R, Wang J, Wang J: Sequencing of 50 human exomes reveals adaptation to high altitude. Science 2010; 329: 75-77.
14. Wenger RH, Stiehl DP, Camenisch G: Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.